AAPS: Intravaginal Ring Releases HIV Drug Over 90 Days

Tenofovir released steadily; similar to or better than gel administration in sheep model

WEDNESDAY, Oct. 17 (HealthDay News) -- An intravaginal ring can steadily release tenofovir over 90 days, similar to or better than a clinically tested gel, according to an experimental study presented at the annual meeting of the American Association of Pharmaceutical Scientists, held from Oct. 14 to 18 in Chicago.

In a sheep model, Todd J. Johnson, M.D., from the University of Utah in Salt Lake City, and colleagues compared the pharmacokinetics of an intravaginal ring filled with a glycerol-based paste containing 65 percent tenofovir with the clinically tested 1 percent tenofovir gel formulation.

The researchers found that intravaginal rings had zero-order release of tenofovir in vitro at levels greater than 10 mg/day for 90 days. Over 90 days, the tenofovir levels were relatively steady, after an initial lag, at 104 ng/g in vaginal tissue, 106 ng/g in vaginal fluid, and 15 ng/mL in plasma. These were similar to or exceeded the levels observed with the tenofovir gel.

"We anticipate that this next-generation ring will be able to release a spectrum of drugs that currently cannot be delivered due to limitations of standard technology," a coauthor said in a statement. "This ring is a breakthrough design because it is highly adaptable to almost any drug; the amount of drug delivered each day is the same and the release rate can be modified easily if needed."

More Information

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events